{"id":"W2463180023","doi":"10.1080/14712598.2016.1205582","title":"Ustekinumab: a novel therapeutic option in Crohn’s disease","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Ustekinumab; Medicine; Crohn's disease; Disease; Expert opinion; Vedolizumab; Monoclonal; Tumor necrosis factor alpha; Intensive care medicine; Monoclonal antibody; Immunology; Internal medicine; Infliximab; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004913948,0.0005810692,0.001129204,0.001489355,0.0002125422,0.0009958441,0.0007070623,0.001360718,0.004825199],"category_scores_gemma":[0.0005370296,0.0001862705,0.0005509287,0.001141367,0.0004030573,0.001105844,0.0006007648,0.002210119,0.002665062],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004370581,"about_ca_system_score_gemma":0.0005687716,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004236262,"about_ca_topic_score_gemma":0.001010407,"domain_scores_codex":[0.9997823,0.0000451339,0.00002868081,0.0000366675,0.00008630817,0.00002094574],"domain_scores_gemma":[0.9997949,0.00009785251,0.00003883198,0.000005453987,0.00004390997,0.00001910665],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008068745,0.00003961545,0.00009651224,0.01487233,0.00008617384,0.0002502291,0.00004346601,0.0001965709,0.001357609,0.003326416,0.027516,0.9521344],"study_design_scores_gemma":[0.00004028219,0.00008546742,0.0004896378,0.006734048,0.000120891,0.002155379,0.00005050678,0.00008756517,0.0003816803,0.002427539,0.9874105,0.00001649043],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00008188709,0.9983015,0.00008219512,0.000505412,0.0002308772,0.00000367323,0.00001331071,0.000004830322,0.0007762054],"genre_scores_gemma":[0.0008254769,0.9979546,0.0001176155,0.0003751792,0.0002329395,0.000005681021,0.00002366507,0.000001164495,0.0004636584],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004825199,"threshold_uncertainty_score":0.01614189,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1118643839363814,"score_gpt":0.380050036030723,"score_spread":0.2681856520943416,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}